<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022732</url>
  </required_header>
  <id_info>
    <org_study_id>20200037586</org_study_id>
    <nct_id>NCT05022732</nct_id>
  </id_info>
  <brief_title>Polyglucosamine L112 in Overweight and Obese Subjects</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Effect on Weight of a Medical Device Based on Polyglucosamine L112Â® in a Group of Overweight and Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda di Servizi alla Persona di Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda di Servizi alla Persona di Pavia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research proposes as its main purpose to evaluate the effectiveness of the intake of&#xD;
      Polyglucosamine at a dose of 3 g / day on weight loss in a group of subjects suffering from&#xD;
      overweight and mild obesity (BMI between 25 and 32 kg / m2). and with weight&gt; 75 kg&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Actual">August 19, 2021</completion_date>
  <primary_completion_date type="Actual">August 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes on anthropometric measures</measure>
    <time_frame>Changes from baseline anthropometric measures at 90 days</time_frame>
    <description>Body weight (Kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on lipid profile</measure>
    <time_frame>Changes from baseline lipid profile at 90 days</time_frame>
    <description>Total Cholesterol (mg/dl), High Density Lipoprotein Cholesterol (mg/dl), Low Density Lipoprotein Cholesterol (mg/dl), Triglycerides (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on insulin resistance</measure>
    <time_frame>Changes from baseline insulin resistance at 90 days</time_frame>
    <description>Homeostasis Model Assessment (pt) for evaluate insulin resistance il &gt; 2,4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on Carbohydrate profile</measure>
    <time_frame>Changes from baseline Carbohydrate profile at 90 days</time_frame>
    <description>Glycemia (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on Carbohydrate profile</measure>
    <time_frame>Changes from baseline Carbohydrate profile at 90 days</time_frame>
    <description>Insulin (mcU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 90 days</time_frame>
    <description>Aspartate aminotransferase (IU/l), alanine aminotransferase (IU/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 90 days</time_frame>
    <description>Gamma glutamyl transferase (U/I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 90 days</time_frame>
    <description>Creatinine (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometric measures</measure>
    <time_frame>Changes from baseline anthropometric measures at 90 days</time_frame>
    <description>Waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometric measures</measure>
    <time_frame>Changes from baseline anthropometric measures at 90 days</time_frame>
    <description>Body Mass Index (Kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on body composition</measure>
    <time_frame>Changes from baseline body composition at 90 days</time_frame>
    <description>Free Fat Mass (g), Fat Mass (g), Visceral Adipose Tissue (g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on oxidative stress</measure>
    <time_frame>Changes from baseline oxidative stress at 90 days</time_frame>
    <description>Reactive Oxygen Species (CARR U)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on oxidative stress</measure>
    <time_frame>Changes from baseline oxidative stress at 90 days</time_frame>
    <description>Total Antioxidant Capacity (ORAC U)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipients and gum arabic in tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyglucosamine L112 (750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polyglucosamine L112</intervention_name>
    <description>750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients</description>
    <arm_group_label>Experimental formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>excipients and gum arabic</description>
    <arm_group_label>Control formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  weight &gt; 75 Kg&#xD;
&#xD;
          -  absence of previous diet therapy attempts&#xD;
&#xD;
          -  no fluctuation of at least 3 kg in the previous 3 months&#xD;
&#xD;
          -  Beck Depression Inventory score &lt; 20 pt&#xD;
&#xD;
          -  Binge Eating Scale score &lt; 27 pt&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to shellfish&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  presence of cardiopathies, nephropathies, liver diseases, bronchopneumopathies,&#xD;
             haemopathies, dermopathies, chronic-degenerative diseases of the Central Nervous&#xD;
             System&#xD;
&#xD;
          -  presence of active peptic ulcer, ulcerative colitis, Crohn's disease, celiac disease,&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          -  symptomatic cholelithiasis&#xD;
&#xD;
          -  previous or current neoplasms&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  obesity secondary to endocrinopathies or genetic syndromes&#xD;
&#xD;
          -  significant motor disability or mental retardation&#xD;
&#xD;
          -  major depressive disorder, bulimia, panic disorder, obsessive-compulsive disorder,&#xD;
             post-traumatic stress disorder, bipolar disorder (I or II), schizophrenia&#xD;
&#xD;
          -  previous history or current diagnosis of drug abuse or alcoholism&#xD;
&#xD;
          -  changing in smoking habits or quitting smoking in the last 6 months&#xD;
&#xD;
          -  current use or in the last 3 months of psychoactive drugs or current use or in the&#xD;
             last 12 months of drugs affecting body weight or appetite&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariangela Rondanelli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Casemiro Mondino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda di Servizi alla Persona</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Polyglucosamine</keyword>
  <keyword>Body composition</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

